In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Akebia Therapeutics Inc (NASDAQ: AKBA) closed the day trading at $1.87 down -2.60% from the previous closing price of $1.92. In other words, the price has decreased by -$2.60 from its previous closing price. On the day, 1.82 million shares were traded. AKBA stock price reached its highest trading level at $1.925 during the session, while it also had its lowest trading level at $1.86.
Ratios:
For a better understanding of AKBA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.21 and its Current Ratio is at 1.52.
On August 28, 2023, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $3.75.
Piper Sandler Upgraded its Neutral to Overweight on May 31, 2023, whereas the target price for the stock was revised from $2 to $4.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 13 ’24 when Hadas Nicole R. sold 12,016 shares for $1.26 per share. The transaction valued at 15,140 led to the insider holds 651,243 shares of the business.
Dahan Michel sold 34,840 shares of AKBA for $43,898 on May 13 ’24. The SVP, Chief Operating Officer now owns 672,092 shares after completing the transaction at $1.26 per share. On Feb 29 ’24, another insider, Dahan Michel, who serves as the SVP, Chief Operating Officer of the company, sold 8,661 shares for $1.58 each. As a result, the insider received 13,684 and left with 706,932 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 407998464 and an Enterprise Value of 477176832. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.43. Its current Enterprise Value per Revenue stands at 2.809 whereas that against EBITDA is 108.203.
Stock Price History:
The Beta on a monthly basis for AKBA is 0.73, which has changed by 0.23076928 over the last 52 weeks, in comparison to a change of 0.24933672 over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $2.48, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is -0.31%, while the 200-Day Moving Average is calculated to be 27.81%.
Shares Statistics:
Over the past 3-months, AKBA traded about 2.09M shares per day on average, while over the past 10 days, AKBA traded about 2084690 shares per day. A total of 211.54M shares are outstanding, with a floating share count of 207.61M. Insiders hold about 4.85% of the company’s shares, while institutions hold 24.86% stake in the company. Shares short for AKBA as of 1734048000 were 14069487 with a Short Ratio of 6.74, compared to 1731628800 on 11961601. Therefore, it implies a Short% of Shares Outstanding of 14069487 and a Short% of Float of 6.52.
